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SUMMARY  
New targets for antiviral strategies are needed against human cytomegalovirus (HCMV), a major 
human pathogen. A cell-based screen aimed at finding inhibitors of the viral transcription factor 
Immediate-Early 2 (IE2) was performed in HCMV-infected cells expressing EGFP under the 
control of an IE2-inducible viral promoter. Screening of a library of bioactive small molecules led 
to the identification of several compounds able to inhibit EGFP expression and also HCMV 
replication with potency in the low-micromolar range. Follow-up studies with four selected hits 
indicated that they all block viral DNA synthesis as well as viral Early and Late genes expression. 
Furthermore, mechanistic studies confirmed that the compounds specifically act via inhibition of 
IE2 transactivating activity, thus blocking viral Early gene expression and the progression of virus 
replication. These results provide a proof of concept for identifying small molecules that modulate 
the activity of a microbial transcription factor to control pathogen replication. 
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INTRODUCTION  
Viral transcription factors (vTFs) play pivotal roles not only in virus replication but also in virus-
induced immunopathogenesis. This is achieved by their ability to both activate viral gene 
expression and to reprogram host pathways by interacting with cellular partners. For these reasons, 
vTFs represent attractive targets for drug discovery. However, traditionally, the identification of 
inhibitors of both cellular and microbial TFs activity has been considered very challenging, if not 
impossible. Indeed, TFs have been long considered “undruggable” targets since they lack of 
intrinsic enzymatic activity, but in the recent years this idea has evolved and some modulators of 
TFs involved in pathogenic processes such as cancer progression and virus replication have been 
identified (Fletcher and Prochownik, 2015; Illendula et al., 2015; Makley and Gestwicki, 2013; 
Mousseau et al., 2012; Yan and Higgins, 2013).  
 The Immediate-Early 2 (IE2) protein encoded by human cytomegalovirus (HCMV) 
represents a prototypic vTF. In fact, it is an essential, multi-tasking protein that is involved in many 
events of HCMV replication cycle (Mocarski et al., 2013). IE2 is required to activate the expression 
of viral Early (E) and Late (L) genes, negatively regulates its own expression by acting on the 
Major Immediate Early promoter, and both activates and inhibits cellular gene expression (Marchini 
et al., 2001; Stinski and Petrik, 2008). Importantly, IE2 stimulates the expression of several pro-
inflammatory genes in infected cells, deregulates the host cell cycle, first by inducing its 
progression and then by blocking it before S phase, and hampers the host immune responses 
(Stinski and Petrik, 2008; Taylor and Bresnahan, 2005, 2006). Taken together, there is compelling 
evidence that IE2 is crucial for the progression of HCMV replicative cycle and plays a major role in 
HCMV pathogenesis and host immunomodulation (Mocarski et al., 2013). Thus, it represents a 
promising target for the development of new anti-HCMV agents (Mercorelli et al., 2011; Scholz et 
al., 2001); however, the identification and development of anti-IE2 molecules is hampered by the 
lack of a crystal structure of the protein, making the rational design of drugs an unfeasible strategy. 
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HCMV is a ubiquitous beta-herpesvirus that infects more than 60% of human population 
worldwide. HCMV is also a major human pathogen, which greatly affects HIV/AIDS patients, 
immunocompromised subjects, and transplant recipients, for whom consequences of HCMV 
infection can cause severe diseases and be life-threatening (Nogalski et al., 2014). Moreover, 
HCMV is one of the major causes of congenital defects in newborns (Manicklal et al., 2013). The 
available anti-HCMV drugs are used as both prophylactic and preemptive agents and are all 
targeted at the viral DNA polymerase, which is responsible of the replication of the viral genome 
(Boeckh et al., 2015). However, they suffer from several drawbacks including long-term toxicity, 
unfavorable pharmacokinetic properties, and emergence of viral resistance. None of them has been 
licensed for the treatment of congenital infection; in addition, second-line therapeutics to manage 
drug-resistant viruses are inadequate. Despite the great efforts spent in the last years, also an 
effective and preemptive vaccine is still lacking (Fu et al., 2014); for all these reasons, there is a 
strong need for new anti-HCMV agents. Blocking the viral replication before E gene expression has 
been proposed to be a valid antiviral approach that can also lead to the repression of a series of 
proinflammatory effects due to HCMV infection and responsible for virus-induced pathogenesis 
(Mercorelli et al., 2011; Scholz et al., 2001).  
 To find inhibitors of the vTF IE2, we decided to apply a strategy of drug repurposing and to 
use a cell-based approach that selects compounds acting prior to or during the E gene expression. 
We exploited an engineered HCMV permissive cell line that stably expresses EGFP under the 
control of a prototypic E gene promoter of HCMV, i.e., the DNA polymerase UL54 gene promoter 
(Luganini et al., 2008; Mercorelli et al., 2014a). This strategy led to the identification of a series of 
small molecules (one already FDA-approved) that block the replication of HCMV by inhibiting the 
activity of IE2 and could represent new candidates for anti-HCMV drug discovery. The described 
approach validates a cell-based screening strategy to find small-molecule modulators of the activity 
of a TF that could be potentially exploited for the identification of inhibitors of other TFs involved 
in pathogenic processes and for which a solved crystal structure does not yet exist.
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RESULTS 
 
Optimization of a Cell-Based Assay for Small-Molecule Screening Targeting IE2 
The U373-pUL54-EGFP (named UL54-2F7) and U373-pUL112-113-EGFP (named UL112-113-
1B4) cell lines stably express EGFP under the control of the IE2-dependent UL54 and UL112-113 E 
promoters of HCMV, respectively (Luganini et al., 2008; Mercorelli et al., 2014a). We adapted this 
cell-based system to find compounds that act early in HCMV replication cycle, using the IE2-
dependent transactivation of an E promoter as a readout. A series of experiments were performed in 
order to determine the optimal cell line/cell density/multiplicity of infection (MOI) combination that 
allowed to obtain a substantial and reliable induction of EGFP expression and to detect a significant 
reduction in the presence of an active compound. The antisense oligodeoxynucleotide fomivirsen, 
which blocks IE2 expression (Azad et al., 1993), served as a positive control for the optimization 
and throughout the screening. As reported in Figure S1 in the Supplemental Information (SI), the 
maximal activation of EGFP expression was obtained with the combination of the UL54-2F7 cell 
line infected with HCMV at MOI of 0.5 Plaque Forming Units (PFU)/cell; under these conditions, 
EGFP expression levels in the presence of fomivirsen were comparable to those of the mock-
infected cells (Figure S1). The calculated Z’ factor from the positive and negative controls was 0.79 
(Zhang et al., 1999); thus, we concluded that this experimental setting could be suitable for the 
screening and identification of inhibitors of IE2-dependent activation of viral E promoters. 
Moreover, to verify the progression of HCMV replication beyond the IE2-induced EGFP 
expression, we analyzed by Western Blot (WB) the expression of representative IE, E, and L 
HCMV proteins in U373 UL54-2F7 cells under the same conditions used for the screening. The 
results presented in Figure S2 in the SI clearly demonstrate that in HCMV-infected U373 UL54-
2F7 cells representative viral proteins are expressed, thus indicating that the progression of HCMV 
replication cycle occurs under the conditions used for of the screening. 
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Screening of the Spectrum Collection 
The UL54-2F7 cell line was used for a primary screening of a total of 2,320 compounds, each at the 
concentration of 10 µM. As a positive control for the inhibition of EGFP expression, samples 
treated with fomivirsen were included in each plate. The Z’ factors ranged between 0.59 and 0.76 
and negligible interplate variability was observed. The criterion for an active compound was one 
that exhibited ≥ 50% reduction of the Fluorescence Units (FU) value measured in the infected and 
DMSO-treated cells. In the primary screening, 125 compounds were identified that met this 
criterion (Figure 1A). These compounds were then retested by the same cell-based assay; however, 
when considering the secondary screen results, we excluded those compounds that resulted clearly 
toxic (i.e., induced cell detachment) upon visual inspection of cell monolayers before lysis at 72 h 
post-infection (p.i.). This was done because the reduction in EGFP expression in those cases could 
most likely be due to cytotoxicity rather than to a real inhibitory activity. Taking this into account, 
38 molecules were reconfirmed as active in inhibiting EGFP expression (Figure 1B). Overall, we 
obtained a 1.6% hit rate (38/2,320) when the limits of 50% inhibition in all the replicates and the 
absence of obvious toxicity were applied. This rate is higher than that expected for random high-
throughput screenings (<0.1-0.3%); however, this is most likely due to the fact that the Spectrum 
Collection is not a random library but is composed only by bioactive molecules. In Table S1 in the 
SI is reported the list of the 38 compounds identified by the cell-based screens as able to inhibit 
HCMV-mediated induction of EGFP expression in UL54-2F7 cells with their PubChem Compound 
Identification number and known bioactivities.  
 
Hit Compounds Inhibit the Replication of HCMV in a Dose-Dependent Manner 
To validate the anti-HCMV activity of the hits, plaque reduction assays (PRA) with HCMV AD169 
were performed with the 38 molecules from the library, along with the reference compound 
ganciclovir (GCV) as a control, and in parallel their cytotoxicities were tested by MTT assays. As 
reported in Table S1, 27 compounds exhibited an EC50 < 10 µM in PRAs  and 14 of them emerged 
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with a Selectivity Index (SI) ≥ 50. To select the compounds to be further characterized, a high SI 
value was then combined with information present in PubMed and other sources about: i) 
compound toxicological profile, ii) previous use in clinical trials in humans and in pediatric setting, 
iii) pharmacokinetic properties, and iv) commercial availability. In addition, compounds with a 
previously reported anti-HCMV activity likely not involving the inhibition of IE2 activity, i.e., 
berberine, clotrimazole, and papaverine, were excluded (Isler et al., 2005; Hayashi et al., 2007; 
Albrecht et al., 1987). This review process also revealed that some compounds selected by the 
screening may be useful as investigational tools but not for anti-HCMV drug repurposing. In fact, 
two of the most potent inhibitors, i.e., isorotenone and hexachlorophene (Table S1), have been 
reported to be associated with long-term toxicity (Evangelista de Duffard and Duffard, 1996; 
Moretto and Colosio, 2011), which is incompatible with their development as anti-HCMV 
therapeutics. At the end of this process, four hit compounds (Table 1), i.e., deguelin (DGN), 
nitazoxanide (NTZ), thioguanosine (TGN), and alexidine dihydrochloride (AXN), were selected 
and purchased for follow-up testing. PRAs and cytotoxicity assays were repeated with the selected 
hits and obtained EC50 curves are reported in Figure 2. As reported in Table 1 and Figure 2, the 
anti-HCMV activity and the lack of significant toxicity were reconfirmed for all of them obtaining 
EC50 values in the low-micromolar range. Since we observed that there was no difference between 
the EC50 values obtained in PRAs performed pretreating the cells for 2 h with test compounds 
before virus infection and EC50 values obtained in assays performed by adding the compounds  2 h 
p.i. (data not shown), in all the experiments for follow-up testing the compounds were added p.i..   
PRAs were then repeated to assess the antiviral activity of the four selected hits against 
different strains of HCMV (including a clinical isolate) and viral strains resistant to ganciclovir or 
foscarnet (two drugs currently used in anti-HCMV therapy targeted at the viral DNA polymerase). 
As reported in Table S2, the EC50 values determined in these experiments were comparable to those 
obtained with the AD169 strain, suggesting that all the selected hits are broad-spectrum inhibitors 
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of HCMV and likely block virus replication with a mechanism that differs from that of the viral 
DNA polymerase inhibitors. 
Given the readout of the expression of EGFP at 72 h p.i. in the screening, we performed 
time-of-addition studies in HCMV-infected U373 UL54-2F7 cells to determine which phase of the 
virus replication cycle was affected by the hit compounds. As shown in Figure S3 in the SI, all the 
hit compounds act at a step subsequent to that affected by fomivirsen (an IE2 expression inhibitor), 
since their addition started losing inhibitory effects from 8 to 24 h p.i., a time frame compatible with 
the transition from IE to E phase during HCMV replication cycle.   
 
Hit Compounds Block the Onset of HCMV DNA Synthesis 
To investigate deeper the antiviral mechanism of the selected compounds, we next tested the effects 
of the selected hits on viral DNA synthesis in HCMV-infected cells, a step subsequent to viral E 
gene expression. To this aim, quantitative PCR (qPCR) was performed from HCMV-infected 
Human Foreskin Fibroblast (HFF) cells treated with DGN, NTZ, TGN, AXN, or WC5, a 6-
aminoquinolone already reported to inhibit HCMV DNA synthesis, as a control (Loregian et al., 
2010; Massari et al., 2013). As reported in Figure 3, HCMV DNA synthesis was inhibited by the 
treatment with all the tested hits and with WC5, as expected (Loregian et al., 2010). Thus, all the 
selected hits prevent the onset of HCMV DNA synthesis, demonstrating that they target an event in 
the HCMV replication cycle that precedes or takes place during virus DNA replication.  
 
Hit Compounds Halt HCMV Replication Cycle Beyond the IE Phase 
To support further the above conclusion, we investigated the effects of the hit compounds on the 
expression of newly synthesized HCMV proteins by WB. To this aim, total cell extracts were 
prepared at various times p.i. from HCMV-infected HFF cells treated with DGN, NTZ, TGN, and 
AXN. The general transcription inhibitor actinomycin D (ActD) and WC5 were included as 
controls. Then, the extracts were analyzed for their content of representative Immediate-Early (IE1 
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and IE2), Early (UL44) and Late (UL55 and UL99) proteins. As expected from its mode of action, 
no viral proteins were detected in the ActD-treated cells (Figure 4). In keeping with previous reports 
(Loregian et al., 2010; Mercorelli et al., 2014b), at 48 h p.i. the expression of the E protein UL44 
was strongly reduced by WC5 (Figure 4), while it had no effect on IE proteins synthesis. When the 
selected hits were considered, none of the compounds significantly affected the expression of IE 
proteins at any of the time points considered (Figure 4, panels A to D). In contrast, treatment with 
DGN, NTZ, TGN, and AXN reduced UL44 expression in a manner similar to WC5 (Figure 4). 
Moreover, a strong inhibitory effect on the expression of L proteins (UL55 and UL99) was 
observed for all of the tested molecules at 72 h p.i. (Figure 4). Overall, these results showed that 
DGN, NTZ, TGN, and AXN affect HCMV replication by acting at an E phase of the viral 
replicative cycle after the IE proteins expression, but before the E and L proteins expression, in 
keeping with the results obtained from the time-of-addition experiments (Figure S3) and the studies 
on viral DNA synthesis (Figure 3). 
 
Hit Compounds Inhibit IE2-Dependent Transactivation of HCMV E Promoters 
The results presented above and the features of cell-based assay employed for the screening 
suggested that the selected hit compounds could act by inhibiting the IE2-mediated E gene 
transactivation. To test this hypothesis, the indicator cell line UL54-2F7, already used for the 
screening, was transduced with adenoviral vectors either expressing IE2 (AdVIE2) or E. coli β-
galactosidase (AdVLacZ) as a control (Mercorelli et al., 2014b; Supplemental Figure S4). 
Subsequently, cells were treated with DNG, NTZ, TGN, and AXN to examine their effects on 
EGFP expression. WC5 and fomivirsen were included as controls. As shown in Figure 5A (left 
panel), IE2 overexpression resulted in EGFP expression; in contrast, a strong inhibition of EGFP 
expression was observed in the cells treated with all test compounds. These results were confirmed 
by a quantitative microscopic analysis of EGFP-positive cells that showed a 70-80% reduction in 
EGFP expression upon treatment of IE2-overexpressing cells with test compounds (Figure 5A, right 
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panel), similar to that obtained with WC5 and fomivirsen. A comparable inhibitory activity of the 
hit compounds on the IE2-dependent transactivation was also observed with the UL112-113 E gene 
promoter (Figure 5B), thus indicating an interference with the IE2-dependent transactivation of two 
different E gene promoters of HCMV. 
To support further this conclusion, we examined the effects of the four selected compounds 
on the UL54 gene promoter activity in a different format of cell-based assay. To this end, a 
luciferase reporter plasmid containing the entire UL54 promoter (pUL54-0.4) was first transfected 
into HFFs that were then transduced with AdVIE2 or AdVLacZ as a control. Two hours later, cells 
were treated with the selected hits (and WC5 and fomivirsen as controls) and the luciferase activity 
was assessed after 48 h. As reported in Figure 5C, in agreement with the results described above 
(Figure 5A), the IE2-dependent transactivation of the UL54 promoter was inhibited by the treatment 
with all the tested compounds. Noteworthy, similarly reduced levels of reporter gene activity were 
observed when the transfection-transduction assays were performed using a luciferase reporter 
construct driven by a minimal UL54 promoter (pUL54-0.15, with 0.15 kbp upstream from the 
transcription start site, Figure 5C). Altogether, these results indicate that the selected hits target the 
IE2-dependent transactivation of viral E gene promoters. 
 
IE2 Inhibitors Do Not Interfere with the Transactivating Activity of Another HCMV TF 
To examine the specificity of the four hits’ inhibitory effect on the IE2 transactivating activity, we 
investigated their effects on the activity of another HCMV-encoded vTF, i.e., the Immediate-Early 
1 (IE1) protein. IE1 is the other major protein product of the HCMV MIE locus and shares with IE2 
the first 85 amino acids (Stinski and Petrik, 2008). In a previous study, we demonstrated that the 
cellular human thymidylate synthase (TS) gene promoter is transactivated by both HCMV and the 
IE1 protein in quiescent fibroblasts (Gribaudo et al., 2002). Thus, we investigated the effects of the 
hit compounds on the IE1-dependent transcriptional activation of TS promoter. As shown in Figure 
6, in transient transfection experiments performed in HFFs, all the tested compounds did not affect 
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the IE1-dependent transactivation of human TS promoter (Gribaudo et al., 2002). The IE2-specific 
inhibitor WC5, used as a control, was ineffective in interfering with the IE1-mediated activation of 
the cellular gene promoter, as expected (Mercorelli et al., 2014b). Together, these results indicated 
that the four selected hit compounds are endowed with an inhibitory activity that is specific for IE2 
over IE1.  
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DISCUSSION 
In this paper, we describe a target-based drug repurposing screen to identify molecules able to 
inhibit the activity of an essential transcription factor encoded by HCMV and hence pathogen 
replication. IE2 has emerged as an attractive antiviral target for new anti-HCMV drug discovery 
(Mercorelli et al., 2011; Scholz et al., 2001) and we recently identified a small molecule, the 6-
aminoquinolone WC5, as a specific inhibitor of IE2 functions essential for optimal viral replication 
(Mercorelli et al., 2009; Loregian et al., 2010; Mercorelli et al., 2014b). The identification of the 
mechanism of action of this compound gave us the proof of principle that IE2 is a druggable target 
and that the modulation of its activity by small molecules is possible. Not only IE2 is the major 
transactivator of viral E gene expression, but it also establishes a strict interplay with several 
cellular pathways that result modulated and hijacked to promote HCMV replication in the host cell. 
For this reason, we thought that a drug repurposing approach could successfully lead to the 
discovery of new IE2 inhibitors and therefore we screened a small-molecule library that consists of 
2,320 bioactive molecules including all FDA-approved drugs.  
The screening assay was based on the exploitation of a HCMV-permissive cell line stably 
transfected with an EGFP reporter under the control of the promoter of the prototypic viral E gene 
UL54, which encodes the DNA polymerase. Upon infection with HCMV, EGFP expression is 
induced by the IE2-dependent transactivation of UL54 promoter. Treatment with compounds able to 
interfere with this event or upstream viral functions leads to a quantifiable reduction in EGFP 
expression. From the initial screening, 125 compounds emerged as able to reduce the IE2-induced 
EGFP-expression from the UL54 promoter. We then retested these compounds by the same assay 
and finally obtained 38 molecules to be evaluated for their antiviral activity against HCMV. 
Therefore, plaque reduction assays and in parallel cytotoxicity assays were performed in HFF cells. 
Interestingly, we noticed that some of the compounds showing anti-HCMV activity belong to the 
same chemotype (as an example, isorotenone and its derivatives DGN, apotoxicarol and alpha-
toxicarol, Table S1). Moreover, we also found compounds with an already reported early anti-
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HCMV activity, such as berberine (Hayashi et al., 2007), clotrimazole (Isler et al., 2005), and 
papaverine (Albrecht et al., 1987) (Table S1), thus validating our experimental approach. The fact 
that other known anti-HCMV drugs included in the library that have a target other than IE2 (e.g., 
DNA polymerase inhibitors) were not selected by our screening indicates that the strategy was 
specific for the identification of IE2 inhibitors (or compounds acting upstream) and not of any 
HCMV inhibitor.  
For the characterization of the antiviral activity, we selected only four hits, an FDA-
approved drug (NTZ) and three drugs under development (DGN, TGN, and AXN). Other 
compounds with a very promising SI (e.g., hexachlorophene and isorotenone, Table S1) were 
excluded since they are not suitable for clinical use in anti-HCMV therapy due to their long-term 
toxicity. The possibility to exclude a priori some compounds, although very active, based on the 
available information is one of the advantages of the use of the drug repurposing approach. It is also 
important to underline, however, that the active compounds that were not selected as drug 
candidates could anyway represent useful research tools to uncover molecular mechanisms of 
HCMV biology, since they point out possible cellular pathways that might be involved in virus 
replication and thus be a starting point also for other researchers in the scientific community. All the 
four selected hits were reordered separately and confirmed their antiviral activity not only against 
the HCMV AD169 strain, but also against a panel of other HCMV strains, suggesting for all of 
them a broad-spectrum anti-HCMV activity. When the effects on viral DNA synthesis and viral 
proteins expression were analyzed, we observed that all the four hits did not affect the expression of 
IE proteins, while viral DNA synthesis as well as the E and L gene products were significantly 
reduced. These results suggested that the IE2-dependent transactivation of E genes could be a target 
of the four compounds. Indeed, we provided strong evidence that the four hits act via the inhibition 
of an IE2-dependent activity (i.e., transactivation of viral E genes), thus preventing the progression 
of HCMV replication cycle. Figure 5 summarizes the mechanistic analysis of the anti-IE2 activity 
of the four hits. We clearly demonstrated by means of transfection-transduction experiments with a 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
14 
 
recombinant adenovirus expressing IE2 alone that the hits block the IE2-dependent transactivation 
of E genes in the absence of any other HCMV protein and in various experimental settings. 
Importantly, the lack of interference with the transactivating activity of another vTF encoded by 
HCMV, i.e., IE1, which shares 85 N-terminal residues with IE2 (Stinski and Petrik, 2008), strongly 
supports the specificity of the hit compounds towards the IE2-dependent transactivation. During the 
preparation of this manuscript, a paper reporting the screening of an older, smaller version of the 
Spectrum Collection to find early inhibitors of HCMV was published (Gardner et al., 2015). Our 
assay was conceived to find inhibitors of IE2-dependent E gene activation, while the assay 
described by Gardner et al. was designed to find compounds that act by inhibiting IE2 expression, 
and therefore an event that precedes viral E gene expression. This difference can thus explain why 
the hits identified in our screening were not selected by the other approach (Gardner et al., 2015). 
On the other hand, the two hits reported by Gardner et al., convallatoxin and podofillox, fall into the 
list of the compounds that we excluded due to their toxicity at 10 µM. This is in agreement with the 
fact that these two compounds were reported to have CC50 values around 5 µM (Gardner et al., 
2015), thus our test concentration was 2-fold higher that their CC50.  
The results presented here provide evidence of the feasibility of targeting the activity of a 
virus-encoded TF to block HCMV replication. This represents a significant conceptual advance 
over previously identified anti-HCMV compounds, since they were targeted mainly at viral 
enzymes. We have employed and successfully validated an assay for small-molecule screening that 
uses the transactivation of an essential viral gene by a specific virus-encoded TF as readout for the 
screening. Although the library used in this study has a small size, our assay is potentially amenable 
also for high-throughput screening campaigns, since it resulted relatively rapid, robust, easy to 
perform, and reliably quantitative. A similar strategy could be applied for the identification of 
inhibitors of other TFs involved in microbial pathogenic processes. TFs have long been considered 
“undruggable” targets for therapeutic development; however, this paper and others (Fletcher and 
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Prochownik, 2015; Illendula et al., 2015; Mousseau et al., 2012; Yan and Higgins, 2013) provide 
the evidence that small-molecule modulators of TFs activity can be identified by screening.  
Small molecules that modulate IE2 activity might act by different mechanisms, for example 
by disrupting the interaction between IE2 and its cellular/viral partners, by interfering with IE2 
post-translational modifications required for its transactivating functions, and by indirectly affecting 
host molecular pathways intercepted by IE2 and essential to create a cellular environment 
conducive to HCMV replication. Since all the four hits have been already reported to have effects 
on cellular pathways , their antiviral activity could be due most likely to the interference with those 
pathways that in HCMV-infected cells are required for the switch from IE to E phase. For instance, 
DGN, a natural rotenoid derivative, is a known inhibitor of activated Akt, Hsp90 and client proteins 
and is under investigation as an antitumoral agent (Wang et al., 2013; Oh et al., 2007). Being a 
multifunctional signal transduction inhibitor, DGN could interfere with several cellular and viral 
pathways required for the correct progression of HCMV replication. To corroborate this, it has been 
demonstrated that PI3K/Akt inhibitors can block herpesvirus infection (Liu and Cohen, 2015). TGN 
is an analog of guanosine and has been reported to inactivate cellular GTPases activity by depleting 
GTP levels. GTP-binding partners such as Rheb and Rac proteins are required for efficient HCMV 
replication and indeed VX-497, an inhibitor of GTP/dGTP biosynthesis, demonstrated anti-HCMV 
activity (Markland et al., 2000). Moreover, GTP-Rheb activity is necessary for mTOR activation, 
which is required for efficient HCMV replication (Moorman and Shenk, 2010). AXN is an 
antibiotic and a selective inhibitor of the mitochondrial phosphatase Ptpmt1. It was reported that 
treatment with AXN reprograms cellular metabolism from aerobic activity to glycolysis leading to 
hyperactivation of AMPK (Liu et al., 2015). The hyperactivation of AMPK could be detrimental for 
HCMV replication, since it counteracts the PI3K/Akt/mTOR pathway. The only FDA-approved 
drug among the selected hits, NTZ, was initially developed as an oral antiparasitic agent against 
protozoan and helmintic infections, but it also demonstrated antibacterial activity including 
Mycobacterium tuberculosis. More recently, NTZ emerged as a first-in-class broad-spectrum 
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antiviral agent, since it showed activity against 20 different RNA and DNA viruses - but up to this 
report not against HCMV - by interfering with cellular functions necessary for viral replication 
(Rossignol et al., 2009; Stachulski et al., 2011; La Frazia et al., 2013; Rossignol, 2014). Currently, 
NTZ is in Phase 3 clinical trials for treating influenza virus infection (Haffizulla et al., 2014). 
Moreover, NTZ promotes autophagy, activates AMPK, and interferes with several kinases activity 
such as PI3K/Akt/mTOR and mitogen-activated protein kinases (MAPKs) signaling pathways 
(Senkowski et al., 2015; Lam et al., 2012; Fan-Minogue et al., 2013). Furthermore, it depletes ATP-
sensitive intracellular Ca2+ inducing mild endoplasmic reticulum stress (Ashiru et al., 2014). 
HCMV, like other viruses, induces viral and cellular kinases and phosphatases at appropriate times 
in order to mediate a correct temporal expression of viral genes during the course of infection. The 
activity of TFs is regulated within the cell by different mechanisms such as intracellular localization 
and post-translational modifications that can induce conformational changes and/or modification of 
local charge and affect the ability of TFs to interact with other proteins. We thus investigated 
whether the antiviral effect of NTZ against HCMV IE2 could be due to an altered localization of the 
TF, since following NTZ treatment no difference in IE2 expression was detected (Figure 4), while 
the inhibition of IE2-dependent transactivation of viral E promoters was observed (Figure 5). By 
immunofluorescence analysis, we observed that in infected cells treated with NTZ IE2 nuclear 
localization was altered since the protein was partially retained into the cytoplasm (Figure S5). A 
possible explanation of the effect of NTZ on IE2 nuclear localization could be that it interferes with 
the correct and time-regulated phosphorylation status of IE2, resulting in an altered conformation of 
the protein and/or impairment in protein-protein interactions. In fact, the nuclear localization of 
some HCMV proteins, such as the DNA polymerase processivity factor UL44, is regulated by 
phosphorylation (Alvisi et al., 2011). Since NTZ is known to intercept several kinase pathways 
including MAPKs, that have been suggested to be involved in IE2 phosphorylation (Harel and 
Alwine, 1998; Barrasa et al., 2005), it could be possible that the anti-HCMV activity of NTZ might 
be due, at least in part, to altered post-translational modifications of IE2, but this hypothesis has to 
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be tested in the future. In keeping with this, the major protein-protein interactions domains of IE2 
colocalize with domains of IE2 that are phosphorylated (Lukac et al., 1997) and mutations of 
certain phosphorylated residues of IE2 or in vitro phosphorylation of IE2 have been related to the 
modulation of its transactivating properties and its ability to interact with protein partners (Barrasa 
et al., 2005; Waheed et al., 1998).  
The dissection of the mode of action of the hits against IE2 and HCMV replication will be 
object of our future work. Regardless, the IE2 inhibitors that we identified, as well as the other 
compounds with anti-HCMV activity reported in this study, could be starting points for new anti-
HCMV drug discovery. In particular, NTZ, which is already used in clinical practice, could be 
rapidly considered for clinical evaluation for the treatment of HCMV-associated pathogenic 
conditions as well as prophylactic agents to prevent HCMV reactivation in high-risk patients.  
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
18 
 
SIGNIFICANCE  
HCMV is a major human pathogen and new drugs are needed to manage congenital infections and 
the emergence of strains resistant to the currently available anti-DNA polymerase drugs. Using a 
target-based screening assay, a few small-molecule inhibitors of HCMV-encoded IE2 have been 
discovered. These HCMV inhibitors prevent viral DNA synthesis, E and L gene expression as well 
as the IE2-dependent transactivation of viral E promoters. These compounds could be exploited in 
anti-HCMV drug development but also could represent useful tools in elucidating molecular 
mechanisms of HCMV replication. Importantly, the drug repurposing approach that we applied 
resulted in the identification of a molecule - NTZ - that is an already FDA-approved therapeutic; 
moreover, NTZ is also currently being evaluated in phase III clinical trials as a new anti-influenza 
candidate drug. Thus, its further clinical evaluation is strongly recommended. The inhibitors 
described here could be the first anti-HCMV small molecules specifically targeting IE2 functions 
and could be able to fill the gap left in the current anti-HCMV therapeutic options by the DNA 
polymerase inhibitors. Our results, furthermore, open the way to the study of new cellular pathways 
that could be essential for virus replication and eventually reveal new drug targets. 
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EXPERIMENTAL PROCEDURES 
Cells and Viruses 
U373-pUL54-EGFP (clone 2F7) and U373-pUL112-113 (clone 1B4) cells, that stably express 
EGFP under the control of the IE2-dependent early UL54 and UL112-113 promoters of HCMV, 
respectively (Luganini et al., 2008), were grown in Dulbecco Modified Eagle’s Medium (DMEM, 
Life Technologies) with 10% fetal bovine serum (FBS; Life Technologies), 100 U/ml penicillin, 
100 μg/ml streptomycin sulfate (P/S, Life Technologies), and 750 µg/ml of G418 (Life 
Technologies). HFF cells were cultured in DMEM supplemented with 10% FBS, 1 mM sodium 
pyruvate, 2 mM glutamine, and P/S. HCMV strain AD169 (VR-538) was purchased from American 
Type Culture Collection (ATCC, Manassas, VA). HCMV strains resistant to antiviral drugs (all 
obtained from the NIH AIDS Research and Reference Reagent Program, Rockville, MD) were 
previously described (Mercorelli et al., 2009). HCMV TB40-UL32-EGFP (kindly provided by C. 
Sinzger, University of Ulm, Germany) was previously described (Sampaio et al., 2005) as well as 
HCMV VR1814 (kindly provided by G. Gerna, IRCCS Policlinico San Matteo, Pavia, Italy) 
recovered from a cervical swab from a pregnant woman (Revello et al., 2001). Recombinant 
adenoviruses expressing HCMV IE2 or E. coli β-galactosidase (LacZ) were previously described 
(Mercorelli et al., 2014b).  
Plasmids  
The pUL54-luciferase indicator plasmids pUL54-0.4 and pUL54-0.15, containing UL54 promoter-
derived sequences were previously reported (Gariano et al., 2012). The pSGIE72, an IE1 expression 
construct, was generated as described (Klucher et al., 1993). The luciferase indicator construct 
phTS-243/+30 contains a portion of the promoter of the human thymidylate synthase gene (TS) (-
243 and +30 relative to the AUG start codon) (Gribaudo et al., 2002). The pRL-TK vector 
expressing Renilla luciferase was purchased from Promega. 
Spectrum Collection and Chemical Substances  
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The Spectrum Collection was purchased from Microsource Discovery System (Gaylordsville, CT). 
It consists of 2,320 bioactive molecules, including 1,040 FDA-approved drugs, dissolved in 100% 
dimethyl sulfoxide (DMSO) at 10 mM and was stored at -20°C. Fomivirsen (ISIS 2922) was 
synthesized by Metabion International AG (Martinsried, Germany). The anti-HCMV 6-
aminoquinolone WC5 was previously described (Mercorelli et al., 2009). All the other chemical 
substances including the hits for the follow-up studies were purchased from Sigma-Aldrich (St. 
Louis, MO).  
Set Up of a Cell-Based EGFP-Expression Reporter Assay 
The detailed description of the optimization of the cell-based assay for the screening is reported in 
the Supplemental Experimental Procedures. 
Screening Protocol and Data Analysis 
U373 UL54-2F7 cells seeded the day before at 2×104 cells per well in 96-well plates were 
pretreated with test compounds for 2 h prior to infection with HCMV AD169 at MOI of 0.5 
PFU/cell. The compounds of the Spectrum Collection were screened in duplicate in two 
independent plates at a fixed concentration of 10 µM. Control wells with mock-infected cells and 
infected cells treated with either 0.01% DMSO or 5 µM fomivirsen were included in each plate 
during the screening. After the infection, cells were incubated with the compounds for 72 h at 37°C. 
Finally, cells were lysed and EGFP expression was determined as described in the Supplemental 
Experimental Procedures. The total screening time for each compound was approximately 5 days. 
The quality of the screening assay was determined as described in (Zhang et al., 1999) by 
calculating the Z’ score of each plate according to Equation 1:  
Z’ = 1 - ( |3σC+  +  3σC- |  /  |3µC+  -  3µC- | )                                         (Equation 1) 
where C+ are the Fluorescence Units (FU) in the cells treated with fomivirsen and C- are the FU in 
the DMSO-treated cells. For hits selection, a cut-off of 50% of inhibitory activity was arbitrarily set. 
The inhibitory activity of each compound was determined according to Equation 2.  
% Activity = (FUCompound / FUC- ) x 100        (Equation 2)  
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Nontoxic compounds with ≥ 50% inhibitory activity in two rounds of screening were selected for 
further characterization.  
Antiviral and Cytotoxicity Assays 
Plaque reduction assays and cytotoxicity assays were performed as previously described in 
Loregian and Coen, 2006.  
Quantitative Real-Time PCR (qPCR) 
To analyze the effects of the hits on viral DNA synthesis, HFFs were seeded at a density of 1.5×105 
per well in 24-well plates. The next day, cells were infected with HCMV AD169 at a MOI of 0.5 
PFU/cell and following virus adsorption (2 h at 37°C), they were incubated with 20 µM DGN, 30 
µM NTZ, 15 µM TGN, 2 µM AXN, or 50 µM WC5 as a control. At 24 and 72 h p.i., cells were 
collected and total DNA and the levels of viral DNA were then determined by qPCR and were 
normalized to the cellular β-globin gene copies (Loregian et al., 2010; Mengoli et al., 2004). The 
oligonucleotide sequences used for the qPCR experiments are reported in the Supplemental 
Information (Table S3). 
Western Blot Analysis 
HFFs were seeded in 6-well plates at a density of 3×105 cells per well. The next day, cells were 
infected with HCMV AD169 at an MOI of 0.5 PFU/cell and following virus adsorption, cells were 
treated with 20 µM DGN, 30 µM NTZ, 15 µM TGN, 2 µM AXN, or with equal volume of DMSO 
(0.1% v/v). Infected samples treated with either 5 μg/ml ActD or 50 μM WC5 were also included. 
Cells extracts collected at 24, 48, and 72 h p.i. were prepared and analyzed as previously described 
(Bronzini et al., 2012). The list of the primary antibodies used in this study is reported in the 
Supplemental Information (Table S4). 
Cell Transfections and Adenoviral Transductions 
For transduction experiments, UL54-2F7 and UL112-113-1B4 cells were seeded at 4.5×104 cells 
per well onto glass coverslips in 24-well plates. Cells were transduced with either AdVIE2 or 
AdVLacZ (MOI of 40 PFU/cell) for 2 h at 37°C, and then treated with 20 μM DGN, 30 μM NTZ, 
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15 μM TGN, 2 μM AXN, 50 μM WC5, 5 μM fomivirsen, or 0.1% v/v of DMSO. At 72 h p.i., cells 
were fixed and mounted with mounting medium (Sigma). Samples were observed with a 20× 
objective under a Olympus IX70 inverted laser scanner confocal microscope equipped with 
FluoView 300 software.  
For transfection and transduction experiments, HFFs were seeded on 24-well plates at 4.5×104 cells 
per well and the following day co-transfected using calcium phosphate (CellPhect Transfection Kit, 
GE Healthcare) with 0.9 µg of pUL54-0.4 or pUL54-0.15 plasmid, and with 0.1 µg of pRL-TK 
plasmid as a control to assess transfection efficiency. At 24 h post-transfection, cells were 
transduced with either AdVIE2 or AdVLacZ at an MOI of 10 PFU/cell for 2 h at 37°C, and then 
treated with 20 μM DGN, 30 μM NTZ, 15 μM TGN, 2 μM AXN, 50 μM WC5, or 0.1% DMSO 
(v/v) for 48 h before determination of luciferase activity.  
For transfection experiment in HFFs, cells were co-transfected with calcium phosphate with 0.3 μg 
of phTS-243/+30 plasmid, 0.6 g of pSGIE72 or pSG5 empty vector, and with 0.05 µg of pRL-TK 
plasmid. At 18 h post-transfection, cells were washed and then maintained in low-serum medium 
and treated with 20 μM DGN, 30 μM NTZ, 15 μM TGN, 2 μM AXN, 50 μM WC5, or 0.1% v/v of 
DMSO for 48 h before determination of luciferase activity. For all the experiments, the values were 
normalized by dividing the values obtained for firefly luciferase by the values obtained for Renilla 
luciferase and expressed as relative luciferase units (RLU). 
Statistical Analysis 
All statistical tests were performed using GraphPad Prism version 5.0 for Windows. Data are 
presented as the means ± standard deviations (SD) of at least two experiments in duplicate. 
 
SUPPLEMENTAL INFORMATION 
Supplemental Information includes five figures, Supplemental Experimental Procedures, and four 
tables and can be found with this article online.  
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FIGURE LEGENDS 
 
Figure 1. Cell-Based Screening Data. Each circle represents the mean % of EGFP expression for a 
given compound tested at 10 µM in duplicate during the primary (A) and secondary screen (B). 
Infected and DMSO-treated cells were considered as exhibiting 100% of EGFP expression. The 
dashed line represents the arbitrary hit cutoff (50% of EGFP expression). In panel B, among the 
compounds with two replicates below 50% of EGFP expression threshold, active (green) 
compounds were distinguished from toxic (red) compounds. Compounds with the means above 
50% were considered inactive (black). 
 
Figure 2. Dose-Dependent Inhibition of HCMV Replication by Hit Compounds Identified in 
the Cell-Based Screening. EC50 curves were obtained by infecting HFF cells with HCMV AD169 
and then treating them with five different concentrations of DGN (A), NTZ (B), TGN (C), and 
AXN (D). Chemical structures of the hits are also reported. Calculated EC50s are indicated. Data 
shown are the means ± SD of three experiments performed in duplicate.  
 
Figure 3. Treatment with the Hit Compounds Blocks Viral DNA Synthesis in HCMV-Infected 
Cells. HFFs were infected with HCMV and then treated with test compounds or DMSO as a 
control. At 24 and 72 h p.i., total DNA was extracted and qPCR was performed with appropriate 
IE2 and β-globin primers. HCMV genomic copies were normalized to the cellular β-globin gene 
copies. Data shown are the means ± SD of three independent experiments performed in duplicate. 
(*p<0.05; **p<0.001, versus calibrator sample [HCMV-infected cells + DMSO] in a paired t test). 
 
Figure 4. Effects of Hit Compounds on the Expression of Representative HCMV IE, E, and L 
Proteins. HFFs were infected with HCMV and then treated with test compounds or DMSO as a 
control. At the indicated times p.i., total cell extracts were prepared and analyzed by WB with anti-
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IEA (IE1 and IE2), anti-UL44, anti-UL55, and anti-UL99 antibodies. Samples treated with either 
ActD or WC5 were also included as controls for inhibition of protein expression at 24 h and 48 h 
p.i., respectively. Tubulin immunodetection served as a loading control.  
 
Figure 5. Hit Compounds Block the IE2-Dependent Transactivation of HCMV E Promoters.  
UL54-2F7 (A) or UL112-113-1B4 (B) cells were transduced with AdVIE2 or with AdVLacZ and 
then treated with test compounds or DMSO as a control. Representative confocal microscopy 
images (EGFP) acquired at 72 h post-transduction (p.t.) are shown (left panel). At the same time, 
confocal microscopy was used to quantify the percentage of EGFP-expressing cells in 20 different 
fields. DMSO-treated transduced cells were considered 100% (right panel). C) HFFs were 
transfected with luciferase reporter plasmids pUL54-0.4 or pUL54-0.15 and after 24 h were 
transduced with AdVIE2 or AdVLacZ. Then, cells were treated with test compounds or DMSO as a 
control. At 48 h p.t., luciferase expression was determined and the transcriptional activity was 
expressed as relative luciferase units (RLU). Data shown are the means ± SD of three experiments 
performed in duplicate. The results presented in all panels were analyzed with Bonferroni post-test 
correction for multiple comparisons. (***p<0.001 versus calibrator sample [AdVIE2 + DMSO]).  
 
Figure 6.  Hit Compounds Do Not Interfere with the IE1-Dependent Transactivation of the 
Cellular Thymidylate Synthetase (TS) Gene Promoter. HFFs were transfected with a luciferase 
reporter plasmid containing a portion of the human thymidylate synthetase promoter (phTS-
243/+30) alone, or co-transfected with a plasmid expressing HCMV IE1 (pSGIE72), or the pSG5 
empty vector, and then treated with test compounds or DMSO as a control. At 48 h post-
transfection, the luciferase activity was determined. Data shown are the means ± SD of three 
independent experiments performed in duplicate. 
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Table 1. Antiviral Activity and Cytotoxicity of the Hit Compounds in Follow-Up Testing 
 
Compound 
(cat. # Sigma) 
PubChem 
CIDa 
Antiviral Activity 
EC50 (µM)b 
Antiviral Activity 
EC90 (µM)c 
Cytotoxicity 
CC50 (µM)d SI
e
 
(-)-Deguelin (D0817) 107935 1.3 ± 1.0 6.5 ± 1.6 > 500 > 357 
Nitazoxanide (N0290) 41684 3.2 ± 0.6 11.8 ± 4.4 285 ± 86 102 
Thioguanosine (858412) 2724387 1.2 ± 0.7 6.0 ± 2.1 > 500 > 357 
Alexidine 
dihydrochloride (A8986) 102678 0.17 ± 0.04 0.44 ± 0.04 14.0 ± 8.5 88 
Ganciclovir (G2536) 3454 3.4 ± 1.1 19.3 ± 1.1 >1000 > 294 
 
aPubChem Compound ID. Compounds data are available in PubChem Compound Database 
(http://pubchem.ncbi.nlm.nih.gov/compound). 
bEC50, compound concentration that inhibits 50% of plaque formation, as determined by PRAs 
against HCMV AD169 in HFF cells. Reported values represent the means ± the SD of data derived 
from three experiments in duplicate. 
cEC90, compound concentration that inhibits 90% of plaque formation. 
dCC50, compound concentration that produces 50% of cytotoxicity, as determined by MTT assays in 
HFF cells. Reported values represent the means ± the SD of data derived from two experiments in 
duplicate.  
eSI, selectivity index (determined as the ratio between CC50 and EC50).  
See also Table S2. 
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Supplemental Figure S1, Related to Figure 1 and Supplemental Experimental Procedures 
 
Figure S1. Optimization of the Cell-Based Assay for the Screening. 
U373 UL54-2F7 and UL112-113-1B4 cell lines were either mock-infected or infected with HCMV 
AD169 at different multiplicity of infection (MOI) and treated with 5 µM fomivirsen as a positive 
control or untreated. EGFP levels (expressed as Fluorescence Units [FU]) in cell-free supernatants 
were determined at 72 h p.i. after cell lysis. All data are represented as mean ± SD of three 
independent experiments; (*p<0.01 versus calibrator sample [HCMV-infected untreated U373 
UL54-2F7 and UL112-113-1B4 cell lines]). 
 
 
Supplemental Figure S2, Related to Figure 1 and Supplemental Experimental Procedures 
 
 
 
Figure S2. Expression of Representative Viral IE, E, and L Proteins in HCMV-Infected U373 
UL54-2F7 Cells. 
U373 UL54-2F7 cells were either mock-infected or infected with HCMV AD169 (MOI 0.5 
PFU/cell). At the indicated times p.i., whole-cell extracts were prepared and analyzed by Western 
Blot (WB) with antibodies specific for IE (IE1 and IE2), E (UL44), and L (UL55 and UL99) 
proteins. Tubulin immunodetection served as an internal control.  
 
 
Supplemental Text & Figures
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Supplemental Figure S3, Related to Figures 3 and 4 and Supplemental Experimental 
Procedures 
 
Figure S3. Effects of Addition of Hit Compounds and Fomivirsen on EGFP Expression at Different 
Time-Points after HCMV Infection of U373 UL54-2F7 Cells. 
U373 UL54-2F7 cells were either mock-infected (N.I.) or infected with HCMV AD169 (MOI 0.5) 
and incubated with 10 µM hit compounds, or DMSO or 5 µM fomivirsen as controls, at the 
indicated times prior or after virus infection. EGFP levels (expressed as Fluorescence Units [FU]) in 
cell-free supernatants were determined at 72 h p.i. after cell lysis. All data are represented as mean 
± SD of three independent experiments. 
 
 
 
Supplemental Figure S4, Related to Figure 5 and Supplemental Experimental Procedures  
 
 
 
 
 
Figure S4. Expression of the IE2 Protein in U373 UL54-2F7 Cells Transduced with AdVIE2. 
U373 UL54-2F7 cells were not transduced (mock) or transduced with AdVIE2 or AdVLacZ at MOI 
of 40 PFU/cell. At the indicated times p.i., whole-cell extracts were analyzed by WB with an anti-
IE2 antibody. Tubulin immunodetection served as an internal control. 
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Supplemental Figure S5, Related to Supplemental Experimental Procedures 
 
 
Figure S5. Intracellular Localization of IE2 in Infected, NTZ-treated HFF Cells.  
The intracellular localization of IE2 in HFF cells infected with HCMV and treated with NTZ or 
DMSO as a control was analyzed by immunofluorescence with an anti-IE2 antibody at 8, 24, and 48 
h p.i.. Nuclei were counterstained with TOTO-3 stain. Individual green (IE2) and blue (TOTO-3) 
channels and merged images are shown. Representative images of four independent experiments 
performed in duplicate are shown. 
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Supplemental Table S1. Table of the Hit Compounds Identified by Cell-based Screens, 
Related to Figure 1 and Experimental Procedures. 
 
 
Compound PubChem CIDa Bioactivity 
Antiviral 
Activity 
EC50 (µM)b 
Cytotoxicity 
CC50 (µM)c SI
d
 
Clotrimazole 2812 Antifungal 0.8 ± 0.6 40 ± 28 50 
Hexachlorophene 3598 Antiinfective  0.3 ± 0.8 150 ± 68 500 
Clioquinol 2788 Antiseptic, antiamebic 4.8 ± 3.6 42 ± 35 9 
Edoxudine 66377 Antiviral > 20 > 200 >10 
Pararosaniline pamoate 11292 Antihelmintic, 
antischistosomal 5.5 ± 1.4 100 ± 36 18 
Nitazoxanide 41684 Antiparasitic 3.9 ± 1.6 >200 >51 
Nisoldipine 4499 Vasodilator (coronary) 3.8 ± 2.6 80 ± 21 21 
Manidipine hydrochloride 4008 Antihypertensive 2.2 ± 2.8 >200 >91 
Miconazole nitrate 68553 Antifungal 1.2 ± 0.6 55 ± 16 46 
Azacitidine 9444 Antineoplastic, 
antimetabolite > 20 > 200 >10 
Papaverine hydrochloride 6084 Muscle relaxant, cerebral 
vasodilator 7.0 ± 2.9 >200 >29 
Hydroxyprogesterone caproate 169870 Progestogen > 20 > 200 >10 
Cycloheximide 6197 Antipsoriatic, protein 
synthesis inhibitor 6.0 ± 1.3 >200 >33 
Pentamidine isethionate 8813 Antiprotozoal ND < 20 ND 
Oligomycin A 5281899 Antibacterial, antifungal ND <  20 ND 
Econazole nitrate 68589 Antifungal 4.9 ± 2.3 85 ± 13 17 
Nitroxoline 19910 Antibacterial 4.5 ± 2.4 100 ± 27 22 
Salinomycin, sodium 53487842 Antibacterial 7.5 ± 1.0 50 ± 18 7 
Dequalinium chloride 10649 Antiinfectant ND < 20 ND 
Berberine chloride 12456 Antiarrhythmic, α2 
agonist, anticonvulsant 1.3 ± 0.8 > 200 >160 
Ethaverine hydrochloride 13796 Antispasmodic 5.0 ± 1.7 > 200 >50 
Tioxolone 72139 Antiseborrhoic > 20 > 200 >10 
Alexidine dihydrochloride 102678 Antibacterial 0.22 ± 0.2 15 ± 5 68 
Isorotenone 6453092 Natural substance < 0.2 > 200 >1000 
Antimycin A 3084471 Antifungal, antiviral 1.4 ± 0.9 > 200 >143 
Pyrromycin 196990 Antibacterial 0.2 ± 0.6 30 ± 8 137 
Mundulone acetate 4587968 Natural substance > 20 > 200 >10 
Ergosterol acetate 444679 Provitamin > 20 > 200 >10 
Deguelin(-) 107935 Antineoplastic, antiviral, insecticide 0.6 ± 0.9 > 200 > 333 
Perseitol 441436 Natural substance 6.0 ± 1.5 >200 >33 
Duartin(-) 3666064 Natural substance 0.9 ± 0.4 > 200 > 235 
Mundoserone 3083809 Natural substance 6.1 ± 2.5 >200 >33 
Rotenonic acid 4303568 Natural substance > 20 > 200 >10 
Thioguanosine 2724387 Antineoplastic 0.7 ± 1.2 >200 >308 
2,4-dinitrophenol 1493 Uncouples oxidative phosphorylation 5.8 ± 1.7 100 ± 18 18 
Apotoxicarol ND Natural substance 15.2 ± 8.6 > 200 > 13 
Alpha-toxicarol 442826 Natural substance 3.2 ± 0.6 110 ± 27 31 
Pentachlorophenol 992 Insecticide, herbicide 6.3 ± 1.1 75 ± 8 137 
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aPubChem Compound ID. Compounds data are available in PubChem Compound Database 
(http://pubchem.ncbi.nlm.nih.gov/compound). 
bCompound concentration that inhibits 50% of plaque formation, as determined by plaque reduction assays against 
HCMV AD169 in HFF cells. Reported values represent the means ± the SD of data derived from two independent 
experiments in duplicate. 
cCompound concentration that produces 50% of cytotoxicity, as determined by MTT assays in HFF cells. Reported 
values represent the means ± the SD of data derived from two independent experiments in duplicate.  
dSI, Selectivity Index (determined as the ratio between CC50 and EC50).  
In boldface are highlighted the compounds selected for follow-up studies; ND, not determined because of cytotoxicity.  
For a comparison with the reference compound GCV, please see the values reported in Table 1 in the main text.   
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Supplemental Table S2. Table of the Antiviral Activity of Selected Hits Against a Panel of 
Different HCMV Strains, Related to Figure 2 and Experimental Procedures.  
 
 
HCMV strain Resistance 
Antiviral Activity  
EC50 (µM)a 
Controlb DGN NTZ TGN AXN 
TB40 None 2.7 ± 1.2 1.1 ± 0.5 3.1 ± 0.1 1.4 ± 0.9 0.16 ± 0.03 
VR1814 None 6.6 ± 0.5 1.4 ± 0.9 3.5 ± 0.6 1.6 ± 1.7 0.23 ± 0.05 
759rD100 GCV 54.2 ± 4.6 2.5 ± 1.9 3.7 ± 0.2 1.5 ± 0.2 0.80 ± 0.07 
PFArD100 FOS, ACV 200 ± 25 1.9  ± 0.1 3.0 ± 0.1 1.9 ± 0.1 0.20 ± 0.08 
 
aEC50, compound concentration that inhibits 50% of plaque formation, as determined by plaque reduction assays. 
Reported values represent the means ± the SD of data derived from three independent experiments in duplicate. 
bGanciclovir (GCV) was used as a control in all plaque reduction assays, except for PFArD100 strain, where foscarnet 
(FOS) was used as a control. ACV: acyclovir. 
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Supplemental Table S3. List of the Oligonucleotides Used in This Study, Related to Figure 3 
and Experimental Procedures. 
 
UL122 qPCR primer set  Primer FOR (CM-5T) TCATCCACACTAGGAGAGCAGACT 
 
Primer REV (CM-3T) GCCAAGCGGCCTCTGAT 
 
Probe ACTGGGCAAAGACCTTCATGCAGATCTC 
β-globin qPCR primer set  Primer FOR AGGGCCTCACCACCAACTT 
 
Primer REV GCACCTGACTCCTGAGGAGAA 
 
Probe ATCCACGTTCACCTTGCCCCACA 
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Supplemental Table S4. List of the Primary Antibodies Used in This Study, Related to Figures 
4, S4, and S5 and Experimental Procedures. 
 
Antigen Supplier Clone ID Usage 
Tubulin  Sigma TUB 2.1 WB (1:2,000) 
IE1/IE2 Argene-Biosoft E13 WB (1:400) 
UL44 Virusys CH16 WB (1:1,000) 
UL55 Virusys CH28 WB (1:1,000) 
UL99 Virusys CH19 WB (1:2,000) 
IE2   Santa Cruz Biotech.         12E2          WB (1:1000); IF (1:100) 
WB: Western Blot; IF: immunofluorescence. 
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Supplemental Experimental Procedures 
 
Optimization of the Cell-Based Assay for the Screening, Related to Figure S1. 
U373 UL54-2F7 and UL112-113-1B4 cells were seeded in 96-well plates at a density of 2×104/well 
and allowed to grow for 16 h. The next day, cells were pretreated for 2 h with 5 µM fomivirsen, and 
then infected with  HCMV AD169 at different multiplicities of infection (MOI, from 0.1 to 10 
PFU/cell). After a 2-h incubation at 37°C, viral inocula were removed and cells were incubated with 
5 µM fomivirsen for 72 h at 37°C. Thereafter, cells were lysed in 0.1 ml of lysis buffer (50 mM 
Tris-HCl pH 7.8, 150 mM NaCl, 5 mM EDTA, 15 mM MgCl2, 0.15% NP-40) for 30 min at 4°C 
and centrifuged. Finally, 90 µl of cell-free supernatants were transferred into 96-well black plates 
(Nunc) to quantify EGFP expression by fluorescence detection with Victor X2 (Perkin Elmer) after 
5 min equilibration.  
 
Analysis of HCMV Proteins Expression in U373 UL54-2F7 Cells by Western Blot, Related to 
Figure S2. 
To verify the completion of the HCMV replication cycle in U373 cells, U373 UL54-2F7 cells were 
seeded in 6-well plates at a density of 3×105/well. The following day, cells were infected with 
HCMV AD169 at MOI of 0.5 PFU/cell for 2 h at 37°C. Whole-cell extracts were then prepared at 
24, 48, and 72 h p.i. as described in the main text, fractionated by 8.5% SDS-PAGE, and then 
analyzed by WB with anti-IEA (IE1/IE2), anti-UL44, anti-UL55, anti-UL99, and anti-tubulin MAbs 
(Table S4).  
Time-of-Addition Studies, Related to Figure S3.  
For time-of-addition studies, U373 UL54-2F7 cells were seeded at  a density of 2×104/well in 96-
well plates and incubated overnight at 37°C. The next day, cells were infected with HCMV AD169 
at MOI 0.5 PFU/cell for 2 h at 37°C. At the end, the viral inocula were removed and at different 
times (-2, 2, 4, 8, 24, 32, 48, 56 h p.i.) the cell medium was replaced with medium containing 10 
µM of the hit compounds or 0.1% DMSO as a control. Cells were incubated at 37°C for a total of 
72 h after infection; at this time point, cells were lysed and EGFP expression was determined as 
previously described.  
Analysis of IE2 Protein Expression in AdVIE2 Transduced-U373 UL54-2F7 Cells by Western 
Blot, Related to Figure S4. 
To verify the expression of the IE2 protein following transduction with AdVIE2, U373 UL54-2F7 
were seeded at a density of  3×105/well in 6-well plates, and then transduced the following day with 
AdVIE2, or AdVLacZ, as a control, at an MOI of 40 PFU/cell. At different times post-infection, 
whole-cell extracts were prepared as described in the main text and analyzed by 8.5% SDS-PAGE 
and WB using anti-IE2 and anti-tubulin MAbs (Table S4).  
Analysis of IE2 Nuclear Localization by Immunofluorescence, Related to Figure S5.  
To analyze the intracellular localization of IE2, HFF cells at a density of 5×105/well seeded on 
coverslips were infected with HCMV AD169 (MOI 0.5) for 2 h at 37°C. At the end of the 
incubation, medium containing 30 µM NTZ, or DMSO as a control, was added and cells were 
incubated at 37°C. At 8, 24, and 48 h p.i., cells were fixed with 4% (v/v) formaldehyde in PBS for 
20 min. After permeabilization with 0.3% Triton X-100 in PBS for 15 min at RT, cells were first 
incubated at RT for 1 h with 4% FBS in PBS, followed by incubation for 1 h at 37°C with an anti-
IE2 Mab (Table S4). Following washes, an anti-mouse IgG FITC-conjugated antibody (Santa Cruz 
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Biotechnology) was added for 1 h at 37°C. Finally, cells were incubated for 20 min at RT with 
TOTO-3 iodide (Molecular Probes) and coverslips were mounted. Cells were imaged with a Leica 
TCS-NT/SP2 confocal microscope with a 40× objective and the images were digitally analyzed 
with Leica software.  
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